Advertisement

Current Urology Reports

, Volume 7, Issue 4, pp 272–281 | Cite as

The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the united states

  • David A. Taub
  • John T. WeiEmail author
Article

Abstract

Throughout the past several decades, interest in health care economics has increased as health care spending has soared—currently in excess of 1.5 trillion dollars and comprising approximately 16% of the nation’s Gross Domestic Product. Benign prostatic hyperplasia (BPH) and its associated clinical manifestation of lower urinary tract symptoms is one of the most common medical conditions of aging men. BPH has been, and continues to be, a major factor in health care expenditures in the United States, costing up to 4 billion dollars each year. During the past 15 years, considerable changes in the patterns of care for BPH patients have evolved, resulting in similarly profound economic alterations. In this article, we examine contemporary trends in practice patterns for BPH and their associated impact on the cost of care for this condition.

Keywords

Benign Prostatic Hyperplasia Lower Urinary Tract Symptom Health Care Expenditure Transurethral Resection Tamsulosin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Platz EA, Smit E, Curhan GC, et al.: Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology 2002, 59:877–883.PubMedCrossRefGoogle Scholar
  2. 2.
    Weis KA, Epstein RS, Huse DM, et al.: The costs of prostatectomy for benign prostatic hyperplasia. Prostate 1993, 22:325–334.PubMedCrossRefGoogle Scholar
  3. 3.
    Saigal CS, Joyce G: Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005, 173:1309–1313. This Urologic Diseases in America study used claims data to estimate the direct and indirect costs of BPH care in working aged men. Treatment of BPH placed a significant burden on employees and their employers through direct medical costs and lost work time. Direct and indirect costs to the private sector related to BPH treatment were estimated at 3.9 billion dollars in 1999.PubMedCrossRefGoogle Scholar
  4. 4.
    Anonymous. By the numbers. health care economics. Modern Healthcare 2003, suppl:2-38.Google Scholar
  5. 5.
    Anderson GF, Hussey PS, Frogner BK, Waters HR: Health spending in the United States and the rest of the industrialized world. Health Affairs 2005, 24:903–914.PubMedCrossRefGoogle Scholar
  6. 6.
    Heffler S, Smith S, Keehan S, et al.: Health spending projections through 2013. Health Affairs Suppl Web Exclusives 2004, W4:79–93, 2004.Google Scholar
  7. 7.
    Woolhandler S, Campbell T, Himmelstein DU: Costs of health care administration in the United States and Canada. N Engl J Med 2003, 349:768–775.PubMedCrossRefGoogle Scholar
  8. 8.
    McConnell JD, Barry MJ, Bruskewitz RC, et al.: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, Number 8. AHCPR Publication No. 94-0582. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; 1994.Google Scholar
  9. 9.
    Goluboff ET, Olsson CA: Urologists on a tightrope: coping with a changing economy. J Urol 1994, 151:1–4.PubMedGoogle Scholar
  10. 10.
    Wei JT, Calhoun E, Jacobsen SJ: Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005, 173:1256–1261. This paper is a summary of the Urologic Diseases in America project chapter on BPH. It details changing trends in the management of BPH throughout the 1990s: a dramatic decrease in the use of transurethral prostatectomy, inpatient hospitalization, and length of hospital stay for this condition, coupled with increasing use of pharmacologic agents and minimally invasive therapies.PubMedCrossRefGoogle Scholar
  11. 11.
    Top 200 Brand-Name Drugs By Retail Sales in 2002. Verispan Scott-Levin, SPA. 2003. Drug Topics. http://www.drugtopics.com/drugtopics/article/articleDetail. jsp?id=104562. Accessed February 21, 2006.Google Scholar
  12. 12.
    Wei JT, Jacobsen SJ, Calhoun E: Benign prostatic hyperplasia. In Urologic Diseases in America: Interim Compendium. Edited by Litwin MS, Saigal CS. Washington, D.C.: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, US Government Publishing Office; 2004:43–70.Google Scholar
  13. 13.
    Projected population of the United States, by age and sex: 2000 to 2050. United States Census Bureau. http:// www.census.gov/ipc/www/usinterimproj/natprojtab02a. pdf. Accessed February 21, 2006.Google Scholar
  14. 14.
    Weiner DM, McDaniel R, Lowe FC: Urologic manpower issues for the 21st century: assessing the impact of changing population demographics. Urology 1997, 49:335–342.PubMedCrossRefGoogle Scholar
  15. 15.
    Jacobsen SJ, Girman CJ, Guess HA, et al.: New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 1995, 155:477–481.PubMedCrossRefGoogle Scholar
  16. 16.
    AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530–547. This update of 1994 AHCPR BPH clinical practice guidelines was developed by a panel of experts chosen by the AUA. The guideline provides an evidence-based approach for the evaluation and management of symptomatic men with BPH.CrossRefGoogle Scholar
  17. 17.
    Holtgrewe HL, Bay-Nielsen H, Carlsson P, et al.: The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia. In Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia. Edited by Denis L, Griffiths K, Khoury S, et al. Plymouth, UK: Plymbridge Distributors, Ltd., 1998:58–76.Google Scholar
  18. 18.
    Gee WF, Holtgrewe HL, Blute ML, et al.: 1997 American Urological Association Gallup survey: changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol 1998, 160:1804–1807.PubMedCrossRefGoogle Scholar
  19. 19.
    Gee WF, Holtgrewe HL, Albertsen PC, et al.: Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 1995, 154:205–206.PubMedCrossRefGoogle Scholar
  20. 20.
    Holtgrewe HL, Mebust WK, Dowd JB, et al.: Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 1989, 141:248–253.PubMedGoogle Scholar
  21. 21.
    Barry MJ, Fowler FJ Jr, Bin L, Oesterling JE: A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 1997, 158:488–491.PubMedCrossRefGoogle Scholar
  22. 22.
    Holtgrewe HL: The medical management of lower urinary tract symptoms and benign prostatic hyperplasia. Urol Clin North Am 1998, 25:555–569; vii.PubMedCrossRefGoogle Scholar
  23. 23.
    Wasson JH, Bubolz TA, Lu-Yao GL, et al.: Transurethral resection of the prostate among Medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases. J Urol 2000, 164:1212–1215.PubMedCrossRefGoogle Scholar
  24. 24.
    Lu-Yao GL, Barry MJ, Chang CH, et al.: Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 1994, 44:692–698.PubMedCrossRefGoogle Scholar
  25. 25.
    Wennberg JE, Mulley AG Jr, Hanley D, et al.: An assessment of prostatectomy for benign urinary tract obstruction: geographic variations and the evaluation of medical care outcomes. JAMA 1988, 259:3027–3030.PubMedCrossRefGoogle Scholar
  26. 26.
    Litwin MS, Sacher SJ, Cohen WS: The resource-based relative value scale: methods, results and impacts on urology. J Urol 1993, 150:981–987.PubMedGoogle Scholar
  27. 27.
    Holtgrewe HL: American Urological Association survey of transurethral prostatectomy and the impact of changing Medicare reimbursement. Urol Clin North Am 1990, 17:587–593.PubMedGoogle Scholar
  28. 28.
    Medicare Physician Fee Schedule Look-Up: Centers for Medicare and Medicaid Services, U S Department of Health and Human Services. http://new.cms.hhs.gov/ apps/pfslookup/default.asp. Accessed February 21, 2006.Google Scholar
  29. 29.
    Lotan Y, Cadeddu JA, Roehrborn CG, Stage KH: The value of your time: evaluation of effects of changes in Medicare reimbursement rates on the practice of urology. J Urol 2004, 172:1958–1962.PubMedCrossRefGoogle Scholar
  30. 30.
    Mueller EJ, Zeidman EJ, Desmond PM, et al.: Reduction of length of stay and cost of transurethral resection of the prostate by early catheter removal. Br J Urol 1996, 78:893–896.PubMedGoogle Scholar
  31. 31.
    Wennberg JA: AHCPR and the strategy for health care reform. Health Affairs 1992, 11:67–71.PubMedCrossRefGoogle Scholar
  32. 32.
    Top 200 Brand-Name Drugs By Retail Sales In 2004: NDCHealth Pharmaceutical. 2005. RxList The Internet Drug Index. http://www.rxlist.com/top200_sales_2004. htm. Accessed February 21, 2006.Google Scholar
  33. 33.
    Sherman D, Bradshaw A, Tanamor M, Topoleski C: Factors affecting the growth of prescription drug expenditures. The National Institute for Health Care Management Research and Educational Foundation 1999, 1–29. http://www.nihcm.com. Accessed February 21, 2006.Google Scholar
  34. 34.
    Larson TR: Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy. Urology 2002, 59(suppl 1):12–16.PubMedCrossRefGoogle Scholar
  35. 35.
    Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL: Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995, 46:477–483.PubMedCrossRefGoogle Scholar
  36. 36.
    Albertsen PC, Pellissier JM, Lowe FC, et al.: Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin Ther 1999, 21:1006–1024.PubMedCrossRefGoogle Scholar
  37. 37.
    Chirikos TN, Sanford E: Cost consequences of surveillance, medical management, or surgery for benign prostatic hyperplasia. J Urol 1996, 155:1311–1316. This is one of the only studies to evaluate long-term costs associated with BPH care. The cost-effectiveness of each type of therapy differs by the age of the patient at which treatment is initiated, with medical therapy having a cost advantage when initiated when the patient is over te age of 70 years, and surgical therapy having a cost advantage for those under the age of 70 years.PubMedCrossRefGoogle Scholar
  38. 38.
    Naslund MJ, Carlson AM, Williams MJ: A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period. J Urol 2005, 173:2090–2093.PubMedCrossRefGoogle Scholar
  39. 39.
    Starkman JS, Santucci RA: Comparison of bipolar transurethral resection of the prostate with standard transurethral prostatectomy: shorter stay, earlier catheter removal, and fewer complications. BJU Int 2005, 95:69–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA: Costeffectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. J Manage Care Pharm 2004, 10:412–422.Google Scholar
  41. 41.
    Blute M, Ackerman SJ, Rein AL, et al.: Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia. Part II: results. Urology 2000, 56:981–987.PubMedCrossRefGoogle Scholar
  42. 42.
    Baladi JF, Menon D, Otten N: An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 1996, 9:443–454.PubMedGoogle Scholar
  43. 43.
    Walden M, Acosta S, Carlsson P, et al.: A cost-effectiveness analysis of transurethral resection of the prostate and transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: two-year follow-up. Scand J Urol Nephrol 1998, 32:204–210.PubMedCrossRefGoogle Scholar
  44. 44.
    Keoghane SR, Lawrence KC, Gray AM, et al.: A doubleblind, randomized, controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up. BJU Int 2000, 85:74–78.PubMedCrossRefGoogle Scholar
  45. 45.
    Hillman AL, Schwartz JS, Willian MK, et al.: The costeffectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996, 47:169–178.PubMedCrossRefGoogle Scholar
  46. 46.
    Foley CL, Taylor C, Kirby RS: Counting the cost of treating benign prostatic hyperplasia. BJU Int 2004, 93:250–252.PubMedCrossRefGoogle Scholar
  47. 47.
    McDonnell J, Busschbach JJ, Kok E, et al.: Lower urinary tract symptoms suggestive of benign prostatic obstruction: triumph. Health-economical analysis. Eur Urol 2001, 39(suppl 3):37–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Drummond MF, McGuire AJ, Black NA, et al.: Economic burden of treated benign prostatic hyperplasia in the United Kingdom. Br J Urol 1993, 71:290–296.PubMedGoogle Scholar
  49. 49.
    Blomqvist P, Ekbom A, Carlsson P, et al.: Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. Urology 1997, 50:214–219.PubMedCrossRefGoogle Scholar
  50. 50.
    Holtgrewe HL: Economic issues and the management of benign prostatic hyperplasia. Urology 1995, 46(suppl A):23–25.PubMedCrossRefGoogle Scholar
  51. 51.
    Ahlstrand C, Carlsson P, Jonsson B: Estimated total costs of treating benign prostatic hyperplasia in Sweden. Scand J Urol Nephrol 1995, 29:57–63.PubMedGoogle Scholar
  52. 52.
    Di Silverio F, D’Eramo G, Flammia GP, et al.: Cost effectiveness in the management of benign prostatic hyperplasia: Italian data. Minerva Urol Nefrol 1994, 46:93–99.Google Scholar
  53. 53.
    Noble SM, Coast J, Brookes S, et al.: Transurethral prostate resection, noncontact laser therapy, or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. J Urol 2002, 168:2476–2482.PubMedCrossRefGoogle Scholar
  54. 54.
    Puppo P: Long-term effects on BPH of medical and instrumental therapies. Eur Urol 2001, 39(suppl 6):2–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Lanes SF, Sulsky S, Walker AM, et al.: A cost density analysis of benign prostatic hyperplasia. Clin Ther 1996, 18:993–1004.PubMedCrossRefGoogle Scholar
  56. 56.
    www drugstore com. Accessed on February 21, 2006.Google Scholar
  57. 57.
    Manyak MJ, Ackerman SJ, Blute ML, et al.: Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy. J Endourol 2002, 16:51–56.PubMedCrossRefGoogle Scholar
  58. 58.
    Holtgrewe HL: Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 1998, 51(suppl):1–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Ackerman SJ, Rein AL, Blute M, et al.: Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology 2000, 56:972–980.PubMedCrossRefGoogle Scholar
  60. 60.
    Raymond JL, Smith CS: Trends in alpha-blocker treatment of patients with benign prostatic hyperplasia and hypertension: dosing regimens and cost comparisons. Clin Ther 1997, 4:821–829.CrossRefGoogle Scholar
  61. 61.
    McDonald H, Hux M, Brisson M, et al.: An economic evaluation of doxazosin, finasteride, and combination therapy in the treatment of benign prostatic hyperplasia [see comment]. Can J Urol 2004, 11:2327–2340.PubMedGoogle Scholar
  62. 62.
    Altwein JE: Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension. Br J Hosp Med 1997, 58:592–594.PubMedGoogle Scholar
  63. 63.
    Cockrum PC, Finder SF, Ries AJ, Potyk RP: A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. Pharmacoeconomics 1997, 11:550–565.PubMedGoogle Scholar
  64. 64.
    Annemans L, Cleemput I, Lamotte M, et al.: The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. BJU Int 2005, 96:566–571.PubMedCrossRefGoogle Scholar
  65. 65.
    Zeliadt SB, Etzioni RD, Penson DF, et al.: Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005, 118:850–857.PubMedCrossRefGoogle Scholar
  66. 66.
    Gordon AE, Shaughnessy AF: Saw palmetto for prostate disorders. Am Fam Physician 2003, 67:1281–1283.PubMedGoogle Scholar
  67. 67.
    Lowe FC, Fagelman E: Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 1999, 53:671–678.PubMedCrossRefGoogle Scholar
  68. 68.
    Chapple CR, Issa MM, Woo H: Transurethral needle ablation (TUNA): a critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Eur Urol 1999, 35:119–128.PubMedCrossRefGoogle Scholar
  69. 69.
    Kobelt G, Spangberg A, Mattiasson A: The cost of feedback microwave thermotherapy compared with transurethral resection of the prostate for treating benign prostatic hyperplasia. BJU Int 2004, 93:543–548.PubMedCrossRefGoogle Scholar
  70. 70.
    De La Rosette JJ, Floratos DL, Severens JL, et al.: Transurethral resection vs microwave thermotherapy of the prostate: a cost-consequences analysis. BJU Int 2003, 92:713–718.CrossRefGoogle Scholar
  71. 71.
    Norby B, Nielsen HV, Frimodt-Moller PC: Cost-effectiveness of new treatments for benign prostatic hyperplasia: results of a randomized trial comparing the short-term cost-effectiveness of transurethral interstitial laser coagulation of the prostate, transurethral microwave thermotherapy, and standard transurethral resection or incision of the prostate. Scand J Urol Nephrol 2002, 36:286–295.PubMedCrossRefGoogle Scholar
  72. 72.
    Baltussen RM, Wielink G, Stoevelaar HJ, et al.: The economic impact of introducing transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: a scenario analysis. World J Urol 1998, 16:142–147.PubMedCrossRefGoogle Scholar
  73. 73.
    Agirbas I, Tatar M, Kisa A: Benign prostatic hyperplasia: cost and effectiveness of three alternative surgical treatment methods used in a Turkish hospital. J Med Syst 2005, 29:487–492.PubMedCrossRefGoogle Scholar
  74. 74.
    Ahlstrand C, Carlsson P, Jonsson B: An estimate of the lifetime cost of surgical treatment of patients with benign prostatic hyperplasia in Sweden. Scand J Urol Nephrol 1996, 30:37–43.PubMedCrossRefGoogle Scholar
  75. 75.
    Keoghane SR, Lawrence KC, Gray AM, et al.: The Oxford Laser Prostate Trial: economic issues surrounding contact laser prostatectomy. Br J Urol 1996, 77:386–390.PubMedGoogle Scholar
  76. 76.
    Chang PL, Huang ST, Wang TM, et al.: Improvements in the efficiency of care after implementing a clinical-care pathway for transurethral prostatectomy. Br J Urol 1998, 81:394–397.PubMedGoogle Scholar
  77. 77.
    Fraundorfer MR, Gilling PJ, Kennett KM, Dunton NG:Holmium laser resection of the prostate is more costeffective than transurethral resection of the prostate: results of a randomized, prospective study. Urology 2001, 57:454–458.PubMedCrossRefGoogle Scholar
  78. 78.
    Kabalin JN, Butler ED: Costs of minimally invasive laser surgery compared with transurethral electrocautery resection of the prostate. West J Med 1995, 162:426–429.PubMedGoogle Scholar
  79. 79.
    Kaplan SA, Te AE: Transurethral electrovaporization of the prostate: a novel method for treating men with benign prostatic hyperplasia. Urology 1995, 45:566–572.PubMedCrossRefGoogle Scholar
  80. 80.
    van Melick HH, van Venrooij GE, van Swol CF, Boon TA:Cost aspects of transurethral resection of the prostate, contact laser prostatectomy, and electrovaporization. Urology 2004, 63:882–886.PubMedCrossRefGoogle Scholar
  81. 81.
    Dixon CM, Theune C: Evaluating the cost of lasers for the treatment of benign prostatic hyperplasia. J Endourol 1995, 9:189–193.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Department of UrologyTaubman Health Care Center, University of Michigan Health SystemAnn ArborUSA

Personalised recommendations